Is APOE ε4 associated with cognitive performance in early MS?
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received July 14, 2019
- Accepted in final form March 27, 2020
- First Published May 1, 2020.
Author Disclosures
- Sinah Engel,
- Christiane Graetz, MD,
- Anke Salmen, MD,
- Muthuraman Muthuraman, PhD,
- Gerrit Toenges, MSc,
- Björn Ambrosius, PhD,
- Antonios Bayas, MD,
- Achim Berthele, MD,
- Christoph Heesen, MD,
- Luisa Klotz, MD,
- Tania Kümpfel, MD,
- Ralf A. Linker, MD,
- Sven G. Meuth, MD, PhD,
- Friedemann Paul, MD,
- Martin Stangel, MD,
- Björn Tackenberg, MD,
- Florian Then Bergh, MD,
- Hayrettin Tumani, MD,
- Frank Weber, MD,
- Brigitte Wildemann, MD,
- Uwe K. Zettl, MD,
- Gisela Antony, Dipl-Psych,
- Stefan Bittner, MD,
- Sergiu Groppa, MD,
- Bernhard Hemmer, MD,
- Heinz Wiendl, MD,
- Ralf Gold, MD,
- Frauke Zipp, MD,
- Christina M. Lill, MD,
- Felix Luessi, MD;
- for the German Competence Network of Multiple Sclerosis
- Sinah Engel,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christiane Graetz, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Anke Salmen, MD,
NONE
NONE
speaker honoraria and/or travel compensation for activities with Almirall Hermal GmbH, Biogen, Merck, Novartis, Roche, and Sanofi Genzyme; none related to this work.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Swiss MS Society
NONE
NONE
NONE
NONE
NONE
NONE
- Muthuraman Muthuraman, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Gerrit Toenges, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Björn Ambrosius, PhD,
NONE
NONE
Commercial, travel grant, 5000? Novartis for AAN 2016
NONE
NONE
NONE
Celgene GmbH, associate Regional Medical Liaison, since September 2018
NONE
NONE
NONE
NONE
NONE
NONE
FORUM Anschubfinanzierung, Medizinische Faktultät Ruhr Universität Bochum, Förderkennzeichen: F859-15
NONE
NONE
NONE
NONE
NONE
1) Stock Option Celgene/ BMS since 20182) Stock Celgene/ BMS since 20183) Stock Novartis since 20194) Stock Bayer since 2019
NONE
- Antonios Bayas, MD,
(1) Merck Serono (2) Biogen (3) Novartis (4) TEVA (5) Sanofi/Genzyme (6) Roche
NONE
(1) Merck Serono: travel, speaker honoraria (2) Biogen: travel, speaker honoraria (3) Novartis: travel, speaker honoraria (4) TEVA: travel, speaker honoraria (5) Sanofi/Genzyme: travel, speaker honoraria (6) Roche: speaker honoraria
NONE
NONE
NONE
NONE
(1) Merck Serono (2) Biogen (3) Novartis
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Achim Berthele, MD,
NONE
NONE
I received funding for travel and speaker honoraria from Alexion, Bayer Healthcare, Biogen, Genzyme, Merck Serono, Mylan,Novartis, Roche and Teva.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christoph Heesen, MD,
NONE
NONE
NONE
International Journal of MS Care, 2014 until now
NONE
NONE
NONE
NONE
NONE
Received Research grants from Genzyme, Biogen, Roche, Novartis, Merck, Roche.
NONE
Genzyme Sanofi Aventis Biogen Novartis Merck Roche
German Minstery of Research, PI 2012-2016 Hertie Foundation, PI 2014-2016 German Innovation Fond, PI 2018-2021
NONE
NMSS
NONE
NONE
NONE
NONE
NONE
NONE
- Luisa Klotz, MD,
(1) Genzyme (2) Novartis (3) Roche (4) Merck (5) Janssen (6) Alexion
NONE
(1) Novartis, speaker honoraria and travel support (2) Merck Serono, speaker honoraria and travel support (3) Biogen, speaker honoraria and travel support (4) Roche, speaker honoraria and travel support (5) Genzyme, speaker honoraria and travel support (6) Teva, speaker honoraria and travel support (7) Janssen, speaker honoraria and travel support (8) Santhera, speaker honoraria and travel support (9) Grifols, speaker honoraria and travel support (10)Alexion, speaker honoraria and travel support (11)Bayer,speaker honoraria and travel support
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Novartis (2) Biogen (3) Merck
(1) (CRC) SFB TR-128 Impact of dietary factors on the gut-CNS-axis  implications for CNS autoimmunity A08, Project leader, 2016-2020 (2) (CRC) SFB 1009 ÂImmune-cell interactions with endothelial cells and pericytes at the blood-brain- barrier: mechanisms and consequences A03, Sub-project Leader, 2012-2020 (3) CRC; ÂThe role of the nuclear receptor NR4A1 in acute ischemic stroke: pathophysiology, therapy evaluation and human translation';Sub-Project leader, 2018-2020 (4) Federal Ministry of Education and Research (BMBF) Competence Network Multiple Sklerose: ÂMulti-parameter immune cell-profiling: identification of biosignatures to understand heterogeneity, prognosis and treatment response factors in MSÂ, 3.1 Sub-project Leader, 2016-2020 (5) Interdisciplinary Centre for Clinical Research, Münster (IZKF),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Tania Kümpfel, MD,
T. Kümpfel has served on advisory boards for Roche Pharma
NONE
T. Kümpfel has received speaker honoraria from Bayer Healthcare, Teva Pharma, Merck, Novartis Pharma, Sanofi-Aventis/Genzyme, Roche Pharma and Biogen as well as grant support from Novartis and Chugai Pharma in the past.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ralf A. Linker, MD,
Biogen, Celgene, Genzyme, Merck,Novartis, Roche.
NONE
Biogen, Celgene, Genzyme, Merck, Novartis, Roche.
NONE
NONE
NONE
NONE
Biogen, Novartis, Roche.
NONE
NONE
NONE
Biogen, Novartis.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sven G. Meuth, MD, PhD,
(1) German association for Multiple Sclerosis (2) German Society for Neurology (DGN)(3) Neurology Trust (4) Center for Clinical Studies (ZKS) (5) Max Planck Society
NONE
Sven Meuth receives honoraria for lecturing and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi- Aventis, Chugai Pharma, QuintilesIMS and Teva.
(1) PLoS One (editor) (2) DGNeurologie, founding member editorial board
(1)Effectivity of specific FXII/FXIIa inhibitors, particularly rHA-Infestin 4 used to treat neuro- inflammatoral diseases (WO 2013/113774 A1 and EP 2 263 110 A1) (2) Diagnosis of a novel autoimmune disease (European patent; 15001186.4 Â 1402) (3)
NONE
NONE
Sven Meuth receives honoraria for lecturing and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi- Aventis, Chugai Pharma, QuintilesIMS and Teva.
NONE
NONE
NONE
Research is funded by Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Fresenius Medical Care, HERZ Burgdorf, Genzyme, Merck Serono, Novartis, ONO Pharma, Roche, and Teva.
Research is funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgesellschaft (DFG), German Academic Exchange Service, Interdisciplinary Center for Clinical Studies (IZKF) Muenster, German Foundation Neurology, Bundesinstitut für Risikobewertung; Gemeinsamer Bundesausschuss
NONE
Research is funded by Else Kröner Fresenius Foundation, Hertie Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Friedemann Paul, MD,
Novartis OCTIMS study steering committee MedImmune / Viela Bio steering committee
NONE
speaker honoraria and travel grants from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, and Merck Serono, Alexion, Chugai, MedImmune, Shire, Roche, Actelion, Celgene
Academic Editor, PLoS ONE Associate Editor, Neurology Neuroimmunology and Neuroinflammation
NONE
NONE
NONE
consultancies for SanofiGenzyme, BiogenIdec, MedImmune, Shire, Alexion
NONE
NONE
NONE
Research support from from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, Alexion and Merck Serono
German Research Council (DFG Exc 257), Werth Stiftung of the City of Cologne, German Ministry of Education and Research (BMBF Competence Network Multiple Sclerosis), Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program (combims.eu)
NONE
Arthur Arnstein Foundation Berlin, Guthy Jackson Charitable Foundation, National Multiple Sclerosis Society of the USA
NONE
NONE
NONE
NONE
NONE
NONE
- Martin Stangel, MD,
Alexion, Biogen, Bayer Healthcare, Baxalta/Shire/Takeda, Celgene, CSL Behring, Grifols, Janssen, MedDay, Merck- Serono, Novartis, Roche, Sanofi-Genzyme
NONE
Travel and speaker honoraria from Bayer Healthcare, Biogen, CSL Behring, Merck-Serono, Novartis, Roche, Sanofi-Genzyme, and Teva
PLoS ONE, Academic Editor; Multiple Sclerosis International, Editorial Board Member
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Biogen, Merck-Serono, Novartis, Sanofi-Genzyme
Deutsche Forschungsgemeinschaft (DFG), Bundesministerium für Bildung und Forschung (BMBF), EU FP7
NONE
Volkswagenstiftung
NONE
NONE
NONE
NONE
NONE
NONE
- Björn Tackenberg, MD,
Commercial(1) CSL Behring(2) Grifols(3) Biogen(4) Novartis(5) Bayer Healthcare(6) Genzyme(7) UCB(8) Roche(9) GILEAD
NONE
Commercial, speaker honoraria(1) CSL Behring(2) Grifols(3) Octapharma(3) Biogen(4) Novartis(5) Bayer Healthcare(6) Genzyme(7) Roche
NONE
NONE
NONE
F. Hoffmann-La Roche AG, Basel, Switzerland
Commercial, Consultancy fees(1) CSL Behring(2) Grifols(3) Biogen(4) Novartis(5) Bayer Healthcare(6) Genzyme(7) UCB(8) Roche(9) GILEAD
NONE
NONE
NONE
Commercial(1) Biogen(2) Novartis
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Florian Then Bergh, MD,
Speaker honoraria and consultancy fees as a speaker and advisor from Actelion, Bayer Healthcare, Biogen, Merck Serono, Novartis, Roche, Sanofi Genzyme, and TEVA.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Support for investigator-initiated trials from Actelion, Novartis. Travel support to attend scientific meetings, through the employing institution, from Bayer Schering, Biogen, Merck, Novartis and Sanofi Genzyme.
German Federal Ministry of Research; Deutsche Forschungsgemeinschaft (DFG, federal research funding agency)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Hayrettin Tumani, MD,
Alexion, Biogen, Celgene, Merck, Novartis, Roche, Sanofi, Teva
NONE
Speaker honoraria from Alexion, Biogen, Celgene, Merck, Novartis, Roche, Sanofi, Teva
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Sanofi
BMBF
University of Ulm
DMSG
NONE
NONE
NONE
NONE
NONE
NONE
- Frank Weber, MD,
(1) Merck-Serono
NONE
(1) Pfizer (2) Novartis
NONE
NONE
(1) Restless Legs Syndrom, Benckert-Hippius, Springer Verlag, 2019
Sana Kliniken des Landkreises Cham GmbH, Head of neurological clinic, 2 years
NONE
NONE
NONE
NONE
NONE
Federal Ministry of Education and Research (BMBF, Projects Biobanking and Omics in ControlMS as part of the Competence Network Multiple Sclerosis).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Brigitte Wildemann, MD,
Brigitte Wildemann served on scientific advisory boards for Novartis, Sanofi Genzyme, Roche
NONE
Brigitte Wildemann has received personal fees from Biogen, Merck Serono, Novartis Pharmaceuticals, TEVA Pharma, and from Sanofi Genzyme
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Brigitte Wildemann reports grants from Deutsche Forschungsgemeinschaft, Bundesministerium für Forschung und Technologie, grants from Dietmar Hopp Stiftung, grants from Klaus Tschira Stiftung, grants from Merck Serono, Novartis Pharmaceuticals, and from Sanofi Genzyme
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Uwe K. Zettl, MD,
NONE
NONE
Travel compensation for research meetings: (1) Aventis (2) Bayer (3) Biogen (4) Celgene Speakers fee: (1) Almirall (2) Alexion (3) Bayer (4) Biogen (5) Merck (6) Novartis (7) Roche (8) Teva
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Gisela Antony, Dipl-Psych,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) German Ministry of Education and Research, BMBF 01GI1304A, PI
University Marburg, Leader Central Information Office Competence Network Parkinson, 2016
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Stefan Bittner, MD,
NONE
NONE
S.B. has received honoraria for travel or speaker honoria from Biogen Idec, Merck Serono, Novartis, Roche and Sanofi- Genzyme.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sergiu Groppa, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Bernhard Hemmer, MD,
Advisory Boards for Novartis, he has served as DMSC member for AllergyCare, TG Therapeutics and Polpharma Biologics
Me or my institution have received speaker honoraria from Desitin
Excemed
Editorial board member of Jama Neurology, Experimental Neurology and Multiple sclerosis journal
I hold part of two patents; one for the detection of antibodies and T cells against KIR4.1 in a subpopulati on of MS patients and one for genetic determinants of neutralizing antibodies to interferon β
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
German Competence Network for Multiple Sclerosis Synergy Excellence Cluster German Research Foundation Bundesministerium für Bildung und Forschung
NONE
NONE
NONE
NONE
NONE
NONE
- Heinz Wiendl, MD,
(1) Biogen, (2) Evgen (3) MedDay Pharmaceuticals (4) Merck Serono (5) Novartis (6) Roche Pharma AG (7) Sanofi-Genzyme
NONE
(1) Alexion (2) Biogen (3) Cognomed (4) F. Hoffmann-La Roche Ltd. (5) Gemeinnützige Hertie-Stiftung (6) Merck Serono (7) Novartis (8) Roche Pharma AG (9) Sanofi-Genzyme (10) TEVA (11) WebMD Global
(1) PLOS ONE, Editorial board member, since 2013 (2) Neurotherapeutics, since 2013 (3) Recent Patents on Inflammation & Allergy Drug Discovery
NONE
NONE
NONE
(1) Abbvie (2) Biogen (3) IGES (4) Johnson & Johnson (5) Merck (6) Novartis (7) Roche (8) Sanofi-Genzyme (9) Swiss Multiple Sclerosis Society
NONE
NONE
NONE
(1) Bayer Healthcare (2) Bayer Vital (3) Biogen (4) Merck Serono (5) Novartis (6) Sanofi  Genzyme (7) Sanofi US (8) TEVA Pharma
(1) German Ministry for Education and Research (BMBF), 01GI1601E, principal investigator, 2016-2019 (2)Interdisciplinary Centre of Clinical Research (IZKF) Muenster, principal investigator, 2015-2018 (4)PML Consortium, principal investigator, 2016-2018 (5) German Research Foundation, principal investigator,SFB 1009 TP A3 + SFB-TR CRC128 TP A09 + SFB TR CRC128 TP A10, TR CRC128 TP V, TR CRC128 TP Z02 2016- 2020
NONE
(1) Else Kröner Fresenius Foundation (2) Fresenius Foundation (3) Hertie Foundation (4) RE ChildrenÂs Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Ralf Gold, MD,
(1) TEVA Laquinimod DSMB
NONE
Speaker honoraria from Biogen, Genzyme, TEVA, Merckserono, BayerSchering,Celgene, Novartis
SAGE Journal TAND, Experimental Neurology
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
From Roche From Merck From Bayer
NONE
NONE
NONE
NONE
NONE
- Frauke Zipp, MD,
NONE
NONE
(1) Teva, research grant and travel compensation (2) Novartis, research grant, consultation funds and travel compensation (3) Merck Serono, research grant and travel compensation (4) Bayer, research grant and travel compensation (5) Biogen Idec Germany, consultation funds and travel funds (6) Ono, consultation funds and travel funds (7) Genzyme, consultation funds and travel funds (8) Sanofi-Aventis, consultation funds and travel funds (9) Octapharma, consultation funds and travel funds
NONE
NONE
NONE
NONE
(1) Teva (2) Merck Serono (3) Novartis (4) Bayer Healthcare (5) Biogen Idec Germany (6) Ono (7) Genzyme (8) Sanofi-Aventis (9) Octapharma
NONE
NONE
NONE
NONE
(1) DFG CRC128, Spokesperson/PI, 2012-2020 (2) DFG CRC1080, PI, 2013-2020 (3) BMBF KKNMS, Executive Board/PI, 2013-2019 (4) PCORI PRAG-MS, Director Subcontracted Organization, 2017-2021
NONE
Progressive MS Alliance - BRAVEinMS
NONE
NONE
NONE
NONE
NONE
NONE
- Christina M. Lill, MD,
NONE
NONE
NONE
Gene, Frontiers Neurol
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) German Research Foundation (2) Possehl Foundation (3) Renate Maaà Foundation (4) Michael J Fox Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Felix Luessi, MD;
advisory board member for Roche Pharma
NONE
travel grants from Teva Pharma and Merck Serono
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- for the German Competence Network of Multiple Sclerosis
- From the Department of Neurology and Focus Program Translational Neuroscience (FTN) (S.E., C.G., M.M., S.B., S.G., F.Z., C.M.L., F.L.), Rhine Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, Germany; Department of Neurology (A.S.), Inselspital, Bern University Hospital, University of Bern, Switzerland; Department of Neurology (A.S., B.A., R.G.), St. Josef-Hospital, Ruhr-University Bochum; Institute of Medical Biostatistics (G.T.), Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg University Mainz; Department of Neurology (A. Bayas), Klinikum Augsburg; Department of Neurology (A. Berthele, B.H.), Klinikum rechts der Isar, Technical University of Munich; Institut für Neuroimmunologie und Multiple Sklerose (C.H.), Universitätsklinikum Hamburg-Eppendorf; Clinic of Neurology (L.K., S.G.M., H.W.), University Hospital Münster, Westphalian-Wilhelms-University Münster; Institute of Clinical Neuroimmunology (T.K.), Ludwig Maximilian University of Munich; Department of Neurology (R.A.L.), University Hospital Erlangen; NeuroCure Clinical Research Center and Experimental and Clinical Research Center (F.P.), Charité – Universitätsmedizin Berlin and Max Delbrueck Center for Molecular Medicine; Department of Neurology (M.S.), Hannover Medical School; Department of Neurology (B.T.), Philipps-University Marburg; Department of Neurology (F.T.B.), University of Leipzig; Department of Neurology (H.T.), University of Ulm; Clinic of Neurology Dietenbronn (H.T.), Schwendi; Neurology (F.W.), Max-Planck-Institute of Psychiatry, Munich; Neurological Clinic (F.W.), Sana Kliniken des Landkreises Cham; Department of Neurology (B.W.), University of Heidelberg; Department. of Neurology (U.K.Z.), University of Rostock; Central Information Office (CIO) (G.A.), Philipps-University Marburg; and Genetic and Molecular Epidemiology Group (C.M.L.), Lübeck Interdisciplinary Platform for Genome Analytics, Institutes of Neurogenetics and Cardiogenetics, University of Lübeck, Germany.
- Correspondence
Dr. Luessi luessi{at}uni-mainz.de
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.